Id |
Subject |
Object |
Predicate |
Lexical cue |
T24269 |
0-5 |
EX |
denotes |
There |
T26765 |
6-9 |
VBP |
denotes |
are |
T84711 |
10-17 |
VBG |
denotes |
ongoing |
T74304 |
18-26 |
JJ |
denotes |
clinical |
T68003 |
27-33 |
NNS |
denotes |
trials |
T5000 |
34-37 |
IN |
denotes |
for |
T64198 |
38-49 |
NN |
denotes |
tocilizumab |
T83078 |
50-59 |
NN |
denotes |
treatment |
T11331 |
60-62 |
IN |
denotes |
in |
T42834 |
63-71 |
NNS |
denotes |
patients |
T27205 |
72-76 |
IN |
denotes |
with |
T23786 |
77-85 |
JJ |
denotes |
moderate |
T45333 |
86-89 |
CC |
denotes |
and |
T9137 |
90-96 |
JJ |
denotes |
severe |
T27842 |
97-105 |
NN |
denotes |
COVID-19 |
T92236 |
107-116 |
RB |
denotes |
Currently |
T32112 |
116-117 |
-COMMA- |
denotes |
, |
T54987 |
118-121 |
DT |
denotes |
the |
T85855 |
122-125 |
NN |
denotes |
use |
T69355 |
126-128 |
IN |
denotes |
of |
T40115 |
129-140 |
NNP |
denotes |
Tocilizumab |
T10850 |
141-143 |
VBZ |
denotes |
is |
T78367 |
144-155 |
VBN |
denotes |
recommended |
T33042 |
156-159 |
IN |
denotes |
for |
T36466 |
160-168 |
NNS |
denotes |
patients |
T61983 |
169-173 |
IN |
denotes |
with |
T2749 |
174-182 |
NN |
denotes |
COVID-19 |
T17580 |
183-186 |
WP |
denotes |
who |
T69055 |
187-191 |
VBP |
denotes |
have |
T71996 |
192-199 |
VBG |
denotes |
warning |
T59356 |
200-205 |
NNS |
denotes |
signs |
T65527 |
206-208 |
IN |
denotes |
of |
T99769 |
209-214 |
NN |
denotes |
hyper |
T44301 |
215-227 |
NN |
denotes |
inflammation |
T54453 |
227-228 |
-COMMA- |
denotes |
, |
T58078 |
229-231 |
IN |
denotes |
as |
T75237 |
232-235 |
MD |
denotes |
can |
T7496 |
236-238 |
VB |
denotes |
be |
T53845 |
239-247 |
VBN |
denotes |
measured |
T78207 |
248-250 |
IN |
denotes |
by |
T88455 |
251-254 |
NN |
denotes |
IL6 |
T77671 |
254-255 |
-COMMA- |
denotes |
, |
T67481 |
256-264 |
NN |
denotes |
ferritin |
T99390 |
264-265 |
-COMMA- |
denotes |
, |
T23484 |
266-274 |
NN |
denotes |
platelet |
T65701 |
275-281 |
NNS |
denotes |
counts |
T30323 |
281-282 |
-COMMA- |
denotes |
, |
T72053 |
283-295 |
JJ |
denotes |
inflammatory |
T81575 |
296-303 |
NNS |
denotes |
markers |
T96428 |
303-304 |
-COMMA- |
denotes |
, |
T36542 |
305-308 |
CC |
denotes |
and |
T88469 |
309-310 |
NN |
denotes |
H |
T51141 |
311-316 |
NN |
denotes |
score |
T97739 |
317-318 |
-LRB- |
denotes |
[ |
T29313 |
318-320 |
CD |
denotes |
28 |
T54016 |
320-321 |
-RRB- |
denotes |
] |
R13154 |
T85855 |
T7496 |
arg1Of |
use,be |
R13264 |
T44301 |
T99769 |
arg1Of |
inflammation,hyper |
R15083 |
T36542 |
T96428 |
arg1Of |
and,"," |
R15531 |
T77671 |
T99390 |
arg1Of |
",","," |
R16905 |
T68003 |
T84711 |
arg1Of |
trials,ongoing |
R17601 |
T27842 |
T27205 |
arg2Of |
COVID-19,with |
R19206 |
T53845 |
T78207 |
arg1Of |
measured,by |
R21977 |
T81575 |
T30323 |
arg2Of |
markers,"," |
R22400 |
T44301 |
T65527 |
arg2Of |
inflammation,of |
R2282 |
T67481 |
T77671 |
arg2Of |
ferritin,"," |
R26554 |
T83078 |
T5000 |
arg2Of |
treatment,for |
R26904 |
T85855 |
T78367 |
arg2Of |
use,recommended |
R27449 |
T83078 |
T64198 |
arg1Of |
treatment,tocilizumab |
R27501 |
T51141 |
T36542 |
arg2Of |
score,and |
R28465 |
T23786 |
T45333 |
arg1Of |
moderate,and |
R29518 |
T68003 |
T5000 |
arg1Of |
trials,for |
R30062 |
T42834 |
T27205 |
arg1Of |
patients,with |
R34037 |
T68003 |
T74304 |
arg1Of |
trials,clinical |
R35135 |
T36466 |
T69055 |
arg1Of |
patients,have |
R40933 |
T36542 |
T78207 |
arg2Of |
and,by |
R41615 |
T51141 |
T97739 |
arg1Of |
score,[ |
R48731 |
T59356 |
T69055 |
arg2Of |
signs,have |
R4907 |
T85855 |
T10850 |
arg1Of |
use,is |
R53041 |
T58078 |
T92236 |
arg1Of |
as,Currently |
R54223 |
T78367 |
T10850 |
arg2Of |
recommended,is |
R59110 |
T29313 |
T97739 |
arg2Of |
28,[ |
R59576 |
T9137 |
T45333 |
arg2Of |
severe,and |
R60119 |
T36466 |
T17580 |
arg1Of |
patients,who |
R60586 |
T65701 |
T99390 |
arg2Of |
counts,"," |
R61251 |
T2749 |
T61983 |
arg2Of |
COVID-19,with |
R61441 |
T58078 |
T32112 |
arg1Of |
as,"," |
R6154 |
T59356 |
T65527 |
arg1Of |
signs,of |
R66943 |
T85855 |
T54987 |
arg1Of |
use,the |
R66954 |
T24269 |
T26765 |
arg1Of |
There,are |
R68271 |
T30323 |
T36542 |
arg1Of |
",",and |
R71674 |
T85855 |
T75237 |
arg1Of |
use,can |
R72772 |
T59356 |
T71996 |
arg1Of |
signs,warning |
R72983 |
T78367 |
T54453 |
arg1Of |
recommended,"," |
R77316 |
T54016 |
T97739 |
arg3Of |
],[ |
R78533 |
T42834 |
T11331 |
arg2Of |
patients,in |
R83390 |
T51141 |
T88469 |
arg1Of |
score,H |
R84932 |
T53845 |
T7496 |
arg2Of |
measured,be |
R85482 |
T78367 |
T58078 |
arg1Of |
recommended,as |
R87538 |
T85855 |
T53845 |
arg2Of |
use,measured |
R89076 |
T88455 |
T77671 |
arg1Of |
IL6,"," |
R89241 |
T27842 |
T23786 |
arg1Of |
COVID-19,moderate |
R89881 |
T85855 |
T69355 |
arg1Of |
use,of |
R8993 |
T65701 |
T23484 |
arg1Of |
counts,platelet |
R92122 |
T81575 |
T72053 |
arg1Of |
markers,inflammatory |
R92489 |
T40115 |
T69355 |
arg2Of |
Tocilizumab,of |
R92565 |
T99390 |
T30323 |
arg1Of |
",","," |
R92720 |
T36466 |
T61983 |
arg1Of |
patients,with |
R93944 |
T78367 |
T33042 |
arg1Of |
recommended,for |
R94262 |
T68003 |
T26765 |
arg2Of |
trials,are |
R94310 |
T53845 |
T58078 |
arg2Of |
measured,as |
R95470 |
T83078 |
T11331 |
arg1Of |
treatment,in |
R96842 |
T53845 |
T75237 |
arg2Of |
measured,can |
R96954 |
T36466 |
T33042 |
arg2Of |
patients,for |
R97104 |
T27842 |
T9137 |
arg1Of |
COVID-19,severe |